Medications
Semaglutide, Tirzepatide
Monthly Cost
$174 – $283
Speed to Start
Moderate
Compounded Medications
Est. 2025
About novi
novi (joinnovi.com) is a compounded GLP-1 telehealth platform founded in 2025, offering semaglutide and tirzepatide at $174 to $283 per month. Among the newest providers in our directory, novi shows early promise with a 4.4 Trustpilot rating, though across only 10+ reviews.
The early Trustpilot performance is the most notable data point — a 4.4 rating, even with limited volume, suggests initial patients are having positive experiences. This puts novi ahead of several similarly new competitors that have zero reviews or negative ratings. However, 10 reviews is far too few to draw reliable conclusions about consistent service quality.
Clinically, novi operates at the minimum level of service. Provider quality is rated low, with no lab testing, no dietitian access, and medium ongoing support. Trust and compliance transparency is rated low, and cost transparency is medium. Pharmacy partners are not publicly disclosed, and CoA testing status is unknown.
There is no BBB listing, no insurance acceptance, and the standard no-refund-on-shipped-medications policy applies. The pricing is competitive for the compounded market, falling in the mid-range for both semaglutide and tirzepatide.
novi is worth watching as it builds its review base, but the current data is insufficient to recommend it over established competitors. Patients who choose novi should ask about pharmacy sourcing, request a Certificate of Analysis, and understand the limitations of a platform this early in its lifecycle.
At a Glance
Medications Offered
Semaglutide, Tirzepatide
Compounded
Cost & Insurance
- Monthly: $174 – $283
- 6-month estimate: $900 – $1700
- Insurance: No
- Self-pay: Yes
Clinical Features
- Lab testing: No
- Dietitian access: No
- BBB Rating: –
Delivery & Access
- Format: Subcutaneous
- Nationwide telehealth: Yes
- Speed: Moderate
- Spanish-speaking providers: Not available
What the Novi Intake Looks Like
We walked through Novi’s full GLP-1 intake at joinnovi.com ourselves — 36 screens of marketing-padded questionnaire, a single short clinical multi-select, and a checkout with two countdown timers. Here’s what an actual prospective patient encounters before being prescribed.
/ 10
Notably thin. Only ONE clinical condition multi-select with six named items, plus sleep + BP range checks and a lifestyle-willingness gate. MTC and MEN2 family history are not asked anywhere, and there is no pancreatitis, allergy, or medication list. Most of the 36 screens are marketing copy, testimonials, educational interstitials, and pricing/urgency UI rather than clinical questions.
/ 10
Anonymous-friendly clinical questionnaire — name, email, and phone aren’t collected until late. The friction comes from commercial pressure: a Forbes Health “#1” ranking card displayed mid-questionnaire, two countdown timers (14:58 and 07:27), an “ONLY 33 DISCOUNTS LEFT” banner, and per-medication “11,253 / 17,482 patients chose this today” social-proof urgency.
The 8 Stages
Clinical Safety Screens Performed
Novi has the thinnest clinical screening of any compounded provider in our catalog so far. The intake includes only ONE condition multi-select with six named items (kidney, liver, cancer, organ transplant, severe GI, suicidal thoughts) and stops there. MTC and MEN2 family history are not asked anywhere in the visible 36-screen flow — the GLP-1 class FDA black-box warning. There is also no pancreatitis screen, no allergy capture (Yes/No, checkbox, or free-text), no medication list (just Yes/No on past meds), no substance / alcohol / opioid screen, no surgery history Yes/No, and no actual heart-rate range. Sex is collected as a binary Female / Male only. Roughly 70-80% of the 36 screens are marketing, testimonials, educational interstitials, and pricing/urgency UI rather than clinical questions.
Novi’s checkout layers commercial-pressure tactics more aggressively than peer compounded providers in the catalog. Patients see a Forbes Health “Best Overall #1” placement card inserted mid-questionnaire (a paid-placement reassurance disguised as third-party validation), an “ONLY 33 DISCOUNTS LEFT, YOURS IS RESERVED FOR: 14:58” countdown banner on the treatment screen, a separate 07:27 “Only 1 discount left” timer on the treatment-details summary, and per-medication social-proof counters reading “11,253 patients chose this today” for Semaglutide and “17,482 patients chose this today” for Tirzepatide. None of these mechanisms reduce the actual price — the $498 savings on the 3-month plan applies regardless — but they are designed to discourage comparison shopping mid-flow.
Source: GLP-1.Reviews editorial walkthrough on April 30, 2026. We completed every screen of the Novi weight-loss intake at joinnovi.com using a representative GLP-1 candidate persona and stopped before submitting any payment information.
Opens joinnovi.com in a new tab.
Start your GLP-1 weight loss journey with novi today
Medical Disclaimer: This review is for informational purposes only and does not constitute medical advice. GLP-1 medications are prescription drugs that should only be used under the supervision of a licensed healthcare provider. Individual results may vary.
Editorial Independence: GLP-1.Reviews maintains full editorial independence. Our scores are based on verified data and standardized criteria.
